Abigail Nieuwsma, Brandon L Vander Zee, John P Berdahl, Mitch Ibach, Tanner J Ferguson, Daniel Terveen
{"title":"评价肾上腺素-off角膜交联治疗角膜扩张性薄角膜患者的安全性和有效性。","authors":"Abigail Nieuwsma, Brandon L Vander Zee, John P Berdahl, Mitch Ibach, Tanner J Ferguson, Daniel Terveen","doi":"10.1177/25158414231197064","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Corneal cross-linking (CXL) is a safe and effective procedure for slowing keratectasia progression in eyes with a corneal thickness of at least 400 µm. Limited research has evaluated the safety and efficacy of epi-off CXL in corneas thinner than 400 µm.</p><p><strong>Objective: </strong>To evaluate the safety and efficacy of CXL to slow keratectasia progression in eyes with <400 µm preoperative corneal thickness.</p><p><strong>Design: </strong>Retrospective chart review.</p><p><strong>Methods: </strong>This retrospective chart review included 37 eyes who underwent epi-off, iso-osmolar riboflavin corneal CXL with a preoperative thinnest point of the cornea <400 µm and had at least 6-12 months of follow-up. Preoperative and postoperative uncorrected visual acuity, best-corrected visual acuity (BCVA), thinnest point of the cornea, flat keratometry, steep keratometry, maximum keratometry (K<sub>max</sub>), need for penetrating keratoplasty, and cases of endothelial failure were recorded. Data were collected at baseline and months 3, 6, 9, and 12 post-CXL.</p><p><strong>Results: </strong>Following cross-linking, 18 eyes (47%) had improved BCVA, 13 (35%) had an unchanged BCVA, and 6 eyes (16%) had a worse BCVA (<i>p</i> = 0.05). The mean postoperative BCVA was 20/81 (0.61 LogMAR) compared to 20/121 (0.78 LogMAR) preoperatively (<i>p</i> = 0.06). K<sub>max</sub> decreased an average of 1.1 D at 3-month (<i>p</i> = 0.53) and 3.4 D at the furthest follow-up (<i>p</i> = 0.10). At the farthest follow-up, 22.7% of eyes had >1 D of K<sub>max</sub> steepening. No patients required keratoplasty and there were no cases of endothelial failure in the follow-up period.</p><p><strong>Conclusion: </strong>This research supports the safety and efficacy of epi-off, iso-osmolar CXL in eyes with <400 μm baseline corneal thickness with no patients requiring penetrating or endothelial keratoplasty, a trend toward improvement in BCVA, and K<sub>max</sub> flattening. In the future, prospective studies would be helpful to confirm these findings.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"15 ","pages":"25158414231197064"},"PeriodicalIF":2.3000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/49/b5/10.1177_25158414231197064.PMC10504847.pdf","citationCount":"0","resultStr":"{\"title\":\"Evaluating the safety and efficacy of epi-off corneal cross-linking in patients with thin corneas due to keratectasia.\",\"authors\":\"Abigail Nieuwsma, Brandon L Vander Zee, John P Berdahl, Mitch Ibach, Tanner J Ferguson, Daniel Terveen\",\"doi\":\"10.1177/25158414231197064\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Corneal cross-linking (CXL) is a safe and effective procedure for slowing keratectasia progression in eyes with a corneal thickness of at least 400 µm. Limited research has evaluated the safety and efficacy of epi-off CXL in corneas thinner than 400 µm.</p><p><strong>Objective: </strong>To evaluate the safety and efficacy of CXL to slow keratectasia progression in eyes with <400 µm preoperative corneal thickness.</p><p><strong>Design: </strong>Retrospective chart review.</p><p><strong>Methods: </strong>This retrospective chart review included 37 eyes who underwent epi-off, iso-osmolar riboflavin corneal CXL with a preoperative thinnest point of the cornea <400 µm and had at least 6-12 months of follow-up. Preoperative and postoperative uncorrected visual acuity, best-corrected visual acuity (BCVA), thinnest point of the cornea, flat keratometry, steep keratometry, maximum keratometry (K<sub>max</sub>), need for penetrating keratoplasty, and cases of endothelial failure were recorded. Data were collected at baseline and months 3, 6, 9, and 12 post-CXL.</p><p><strong>Results: </strong>Following cross-linking, 18 eyes (47%) had improved BCVA, 13 (35%) had an unchanged BCVA, and 6 eyes (16%) had a worse BCVA (<i>p</i> = 0.05). The mean postoperative BCVA was 20/81 (0.61 LogMAR) compared to 20/121 (0.78 LogMAR) preoperatively (<i>p</i> = 0.06). K<sub>max</sub> decreased an average of 1.1 D at 3-month (<i>p</i> = 0.53) and 3.4 D at the furthest follow-up (<i>p</i> = 0.10). At the farthest follow-up, 22.7% of eyes had >1 D of K<sub>max</sub> steepening. No patients required keratoplasty and there were no cases of endothelial failure in the follow-up period.</p><p><strong>Conclusion: </strong>This research supports the safety and efficacy of epi-off, iso-osmolar CXL in eyes with <400 μm baseline corneal thickness with no patients requiring penetrating or endothelial keratoplasty, a trend toward improvement in BCVA, and K<sub>max</sub> flattening. In the future, prospective studies would be helpful to confirm these findings.</p>\",\"PeriodicalId\":23054,\"journal\":{\"name\":\"Therapeutic Advances in Ophthalmology\",\"volume\":\"15 \",\"pages\":\"25158414231197064\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/49/b5/10.1177_25158414231197064.PMC10504847.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Ophthalmology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/25158414231197064\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/25158414231197064","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:角膜交联(CXL)是一种安全有效的治疗角膜厚度≥400µm的角膜扩张症的方法。有限的研究评估了epi-off CXL在角膜厚度小于400µm时的安全性和有效性。目的:评价CXL延缓眼部角膜扩张进展的安全性和有效性。方法:回顾性回顾了37只眼,这些眼接受了肾上腺素脱落、等渗核黄素角膜CXL(术前角膜最薄点为max)、穿透性角膜移植术和内皮细胞衰竭。在基线和cxl后3、6、9和12个月收集数据。结果:交联后,18只眼(47%)BCVA改善,13只眼(35%)BCVA不变,6只眼(16%)BCVA恶化(p = 0.05)。术后平均BCVA为20/81 (0.61 LogMAR),而术前为20/121 (0.78 LogMAR) (p = 0.06)。Kmax在3个月时平均下降1.1 D (p = 0.53),在最远随访时平均下降3.4 D (p = 0.10)。在最远的随访中,22.7%的眼睛有>1 D的Kmax变陡。在随访期间,没有患者需要角膜移植,也没有内皮细胞衰竭的病例。结论:本研究支持epi-off等渗透性CXL治疗最大扁平化眼的安全性和有效性。在未来,前瞻性研究将有助于证实这些发现。
Evaluating the safety and efficacy of epi-off corneal cross-linking in patients with thin corneas due to keratectasia.
Background: Corneal cross-linking (CXL) is a safe and effective procedure for slowing keratectasia progression in eyes with a corneal thickness of at least 400 µm. Limited research has evaluated the safety and efficacy of epi-off CXL in corneas thinner than 400 µm.
Objective: To evaluate the safety and efficacy of CXL to slow keratectasia progression in eyes with <400 µm preoperative corneal thickness.
Design: Retrospective chart review.
Methods: This retrospective chart review included 37 eyes who underwent epi-off, iso-osmolar riboflavin corneal CXL with a preoperative thinnest point of the cornea <400 µm and had at least 6-12 months of follow-up. Preoperative and postoperative uncorrected visual acuity, best-corrected visual acuity (BCVA), thinnest point of the cornea, flat keratometry, steep keratometry, maximum keratometry (Kmax), need for penetrating keratoplasty, and cases of endothelial failure were recorded. Data were collected at baseline and months 3, 6, 9, and 12 post-CXL.
Results: Following cross-linking, 18 eyes (47%) had improved BCVA, 13 (35%) had an unchanged BCVA, and 6 eyes (16%) had a worse BCVA (p = 0.05). The mean postoperative BCVA was 20/81 (0.61 LogMAR) compared to 20/121 (0.78 LogMAR) preoperatively (p = 0.06). Kmax decreased an average of 1.1 D at 3-month (p = 0.53) and 3.4 D at the furthest follow-up (p = 0.10). At the farthest follow-up, 22.7% of eyes had >1 D of Kmax steepening. No patients required keratoplasty and there were no cases of endothelial failure in the follow-up period.
Conclusion: This research supports the safety and efficacy of epi-off, iso-osmolar CXL in eyes with <400 μm baseline corneal thickness with no patients requiring penetrating or endothelial keratoplasty, a trend toward improvement in BCVA, and Kmax flattening. In the future, prospective studies would be helpful to confirm these findings.